Literature DB >> 12429192

Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

Biljana Georgievska1, Deniz Kirik, Anders Björklund.   

Abstract

The effects of sustained (up to 9 months) striatal overexpression of glial cell line derived neurotrophic factor (GDNF) on lesioned nigrostriatal dopamine (DA) neurons was studied using a recombinant lentiviral (rLV) vector to deliver GDNF into the striatum 4 weeks prior to the creation of an intrastriatal 6-hydroxydopamine lesion. The results of the amphetamine-induced rotation suggested an initial partial protection followed by a complete recovery, whereas the spontaneous motor behaviors remained impaired. There was a clear protection of the nigral tyrosine hydroxylase (TH)-positive neurons in the rLV-GDNF group compared to rats injected with the control vector encoding green fluorescent protein (GFP) (70 and 20% of the intact side, respectively). However, the striatal TH+ fiber density was equally reduced (to 20% of the intact side) in both groups. Further morphological analyses indicated that the nigrostriatal projections of the DA neurons were indeed preserved in the GDNF group. The axonal projections were visualized using two independent methods: First, retrograde labeling of the nigral cell bodies by intrastriatal Fluoro-Gold injections showed that the majority of rescued cells in the GDNF group had preserved axonal projections to striatum. Second, injections of a recombinant adeno-associated viral vector expressing GFP into the nigra was used to anterogradely fill the DA neurons and their projections with GFP protein. GFP immunostaining clearly demonstrated that the fibers of the nigral DA cells were preserved along the nigrostriatal pathway and innervated large parts of the striatum, but did not express TH at detectable levels. In addition, fiber sprouting was observed in the globus pallidus, entopeduncular nucleus, and substantia nigra, corresponding to areas where GDNF protein was released. The lack of functional recovery in the spontaneous motor behaviors may, at least in part, be explained by this extensive aberrant fiber sprouting in the downstream striatal target nuclei and/or decreased synthesis of dopamine in the striatum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429192     DOI: 10.1006/exnr.2002.8006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  64 in total

1.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Regulation of episomal gene expression by KRAB/KAP1-mediated histone modifications.

Authors:  Isabelle Barde; Elisa Laurenti; Sonia Verp; Anna Claire Groner; Christopher Towne; Viviane Padrun; Patrick Aebischer; Andreas Trumpp; Didier Trono
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

3.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

4.  Lentiviral vector-mediated gradients of GDNF in the injured peripheral nerve: effects on nerve coil formation, Schwann cell maturation and myelination.

Authors:  Ruben Eggers; Fred de Winter; Stefan A Hoyng; Kasper C D Roet; Erich M Ehlert; Martijn J A Malessy; Joost Verhaagen; Martijn R Tannemaat
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat.

Authors:  Tinmarla Frances Oo; Vincent Ries; Jinwhan Cho; Nikolai Kholodilov; Robert E Burke
Journal:  J Comp Neurol       Date:  2005-03-28       Impact factor: 3.215

Review 6.  Trophic factors therapy in Parkinson's disease.

Authors:  Shilpa Ramaswamy; Katherine E Soderstrom; Jeffrey H Kordower
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

Review 7.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

8.  Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

Authors:  D Suwelack; A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; K Wawrowsky; P R Lowenstein; M G Castro
Journal:  Gene Ther       Date:  2004-12       Impact factor: 5.250

Review 9.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

10.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.